VARIATION IN TOPOISOMERASE-I GENE COPY NUMBER AS A MECHANISM FOR INTRINSIC DRUG-SENSITIVITY

Citation
Hl. Mcleod et Wn. Keith, VARIATION IN TOPOISOMERASE-I GENE COPY NUMBER AS A MECHANISM FOR INTRINSIC DRUG-SENSITIVITY, British Journal of Cancer, 74(4), 1996, pp. 508-512
Citations number
23
Categorie Soggetti
Oncology
Journal title
ISSN journal
00070920
Volume
74
Issue
4
Year of publication
1996
Pages
508 - 512
Database
ISI
SICI code
0007-0920(1996)74:4<508:VITGCN>2.0.ZU;2-M
Abstract
DNA topoisomerase I (topo I) is the principle target for camptothecin and its derivatives such as SN38. Levels to topo I expression vary wid ely between and within tumour types and the basis for the poorly under stood. We have used fluorescence in situ hybridisation to detect the t opo I locus in a panel of breast and colon cancer cell lines. This app roach has identified a range or topo I gene copies from 1 to 6 between the cell lines as a result of DNA amplification, polysomy and isochro mosome formation. Topo I gene copy number was highly correlated with t opo I expression, (r(s)=0.92), and inversely correlated to sensitivity to a 1 h exposure to SN38 (r(s)=-0.904). This illustrates the signifi cant impact of altered topo I gene copy number on intrinsic drug sensi tivity and influences potential mechanisms for acquisition of drug res istance.